'Truly sorry': Scientists pull panned Lancet study of Trump-touted drug
NEW YORK/LONDON, June 5 (Reuters) - An influential study that found hydroxychloroquine increased the risk of death in COVID-19 patients has been withdrawn a week after it led to major trials being halted, adding to confusion about a malaria drug championed by U.S. President Donald Trump.
The Lancet medical journal pulled the study after three of its authors retracted it, citing concerns about the quality and veracity of data in it. The World Health Organization (WHO) will resume its hydroxychloroquine trials after pausing them in the wake of the study. Dozens of other trials have resumed or are in process.
The three authors said Surgisphere, the company that provided the data, would not transfer the dataset for an independent review and they "can no longer vouch for the veracity of the primary data sources."
The fourth author of the study, Dr. Sapan Desai, chief executive of Surgisphere, declined to comment on the retraction.
The Lancet said it "takes issues of scientific integrity extremely seriously" adding: "There are many outstanding questions about Surgisphere and the data that were allegedly included in this study".
Comentarios